US Closed System Transfer Devices Market

The US closed system transfer devices market is projected to reach USD 0.86 billion by 2031 from USD 0.67 billion in 2026 at a CAGR of 5.0% during the forecast period.

The growing volumes of oncology drugs are supported by stringent regulatory guidelines from OSHA and NIOSH, along with the increasing focus by hospitals on healthcare worker safety, as tenets that have driven the growth of the CSTD market in the US. Several restraints have hindered the growth of the market, such as high costs of devices, challenges in integrating into established workflows, and uneven recent adoption at smaller facilities. However, opportunities exist, including increasing the use of hazardous injectable drugs beyond oncology, growth in the number of ambulatory and home infusion centers, technological advancements that improve usability, and potential future regulatory mandates that could hasten nationwide adoption.

To know about the assumptions considered for the study download the pdf brochure

This report segments the CSTD market by closing mechanism, type, component, technology, and end user.

Prominent players in this market include BD (US), ICU Medical (US), B. Braun Melsungen (Germany),  Corvida Medical (US), JMS (Japan), Equashield (US), Corning Incorporated (US), Terumo Corporation (Japan), Cardinal Health (US), Baxter International (US), and West Pharmaceuticals Services (US), among others.

ICU Medical (US)

With a portfolio of clinically relevant products, ICU Medical has carved out a niche for itself in the CSTD market in the US. Its leading closed system transfer devices, ChemoLock and ChemoClave, promise greater safety and better workflow efficiency in the handling of hazardous drugs. Despite its strong market presence as part of a wider infusion therapy and compounding automation offering, it meets the safety standard defined in USP <800> for its customers. ICU Medical thus competes favorably with other manufacturers in the CSTD space, including BD, as it has built its claim on innovation, has long industry experience, and has a safety ecosystem that ensures adoption and use in major US hospitals and oncology centers.

BD (US)

BD (Becton, Dickinson and Company) is a significant contributor to the US CSTD market since its BD PhaSeal system opened the way for the closed system drug transfer device class and thus propelled early leadership and widespread clinical acceptance in the handling of hazardous drugs. This flagship CSTD eliminates environmental contamination and renders the escaping drug vapor harmless, thereby ensuring added safety for healthcare workers and supporting compliance with stringent US occupational-safety standards. BD's competitive position and market influence on CSTD adoption are maintained through its comprehensive global medical-device infrastructure, strong brand reputation, product innovation, and the upgrade of PhaSeal.

Cardinal Health (US)

Considering its strong position as a national leader in health services and distribution, the company, together with its comprehensive hazardous drug safety portfolio, is a key player in the US CSTD market. Cardinal Health's proprietary closed system transfer devices, pharmacy compounding, and PPE offerings provide hospitals and infusion centers with USP <800> compliance efficiencies. Cardinal Health's business development strategy was to penetrate the market through deep-rooted relationships with health systems, group purchasing organizations, and oncology clinics. In addition, wide-scale reliability, integrated medication-safety workflow optimization capabilities, and supply chain management further support Cardinal Health's leadership position in the US CSTD landscape.

Market Ranking

The US CSTD market is consolidated, with prominent players accounting for 90.0% of the total market share in 2025. Some of the players dominating the market include BD (US), ICU Medical (US), Cardinal Health (US), B. Braun Melsungen (Germany),  Corvida Medical (US), JMS (Japan), Equashield (US), Terumo Corporation (Japan), and Baxter International (US), among others.

A large number of domestic players with significant presence comprise the US CSTD market, with hospital relations in a strong position, along with regulatory compliance capabilities and established distribution networks. Major sources boosting market growth would be the strict adherence to USP <800>, increased volumes of oncology drug preparations, and growing attention to health worker safety. Large companies tend to enjoy bundled portfolios of infusion, pharmacy, and safety that ease the route to acceptance. Smaller and international manufacturers are now slowly capitalizing on the market through cost-effective, user-friendly CSTDs, especially in ambulatory infusion centers and smaller hospitals. These factories seem to be eroding the prices, thereby increasing competition and access in various care environments.

Related Reports:

US Closed System Transfer Devices Market by Closing Mechanism (Color-to-Color Systems), Type (Needleless Systems), Component (Female Components, Male Luer), Technology (Air Cleaning/Filtration Devices), End User (Hospitals Clinics) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com